24hoursworld

new drug shows positive results

new drug shows positive results

However, the results, published Wednesday in the New England Journal of Medicine, also point to side effects, sometimes serious.

In total, 17.3% of patients who received lecanemab experienced brain hemorrhagescompared to 9% of patients in the placebo group.

12.6% of patients treated with lecanemab suffered cerebral edema versus only 1.7% in the placebo group.

brain alzheimer.jpg

personalinjurydoctorgroup

Alzheimer’s mortality

The overall rate is almost the same in the two groups (0.7% in people who received lecanemab, 0.8% for those who received placebo).

“It is the first drug that offers a true treatment option for people with Alzheimer’s”estimated Bart De Strooper, director of the British Institute for Dementia Research.

“Although the clinical benefits seem somewhat limited, it is expected that they will become more evident if the drug is administered for a longer period of time”said.

Why the disease develops

In Alzheimer’s, two key proteins – tau and another called beta-amyloid – gradually accumulate abnormally in the brain, causing brain cell death and brain shrinkage.

This causes memory loss and an increasing inability to perform everyday tasks.

This disease affects more than 40 million people worldwide.

Lecanemab targets amyloid beta protein deposits, but only in the early stages of the disease, which may limit its use, as Alzheimer’s is often diagnosed late.

Source: Ambito

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest Posts